In our meta-analysis, we conducted pooled analysis with the EMPA-REG, CANVAS and CREDENCE trials and found that SGLT2 inhibitors caused a significant 50% reduction in hemorrhagic stroke compared with placebo. This evidence concerns the gene SLC5A2 and hemorrhagic stroke.